Traders should note this is a procedural filing to document existing IP ownership, not a new strategic development. The core value of the patent (for enzymatic ibuprofen synthesis) remains unchanged. Monitor future developments on the patent's status (issuance, commercialization) for potential value inflection points.
Price Chart
Executive Summary
Quantum Genesis AI Corp. filed a confirmatory Intellectual Property Assignment Agreement to formalize its ownership of a patent application for enzymatic ibuprofen synthesis, originally acquired in 2023. The company is amending prior filings to reflect this formalization. This is a routine documentation update, not a new IP acquisition.
Key Facts
- The company entered into a confirmatory IP assignment agreement with its CEO, Naveen Kulkarni, on April 9, 2026.
- The agreement formalizes the transfer of rights to U.S. Patent Application No. US20250146029A1, titled 'Modified Polypeptides for Enzymatic Synthesis of Ibuprofen', originally acquired under an Asset Purchase Agreement dated February 21, 2023.
- The assignment is effective retroactively to November 2, 2023, the filing date of the patent application.
- The company is amending its 2025 10-K and 2025/2026 10-Qs to update disclosures regarding this IP.
- No new financial terms or consideration were disclosed, as this is a confirmatory agreement for a prior transaction.
Financial Impact
No immediate financial impact. This is a legal formalization of a prior 2023 transaction.
Risk Factors
- The patent application has not yet been granted, so there is no guaranteed IP protection.
- The commercial viability of the enzymatic synthesis technology is unproven and faces potential technical or market adoption hurdles.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001477932-26-002252 |
| Document: qtzm_ex101.htm | 0001477932-26-002252 |
| Document: 0001477932-26-002252-index-headers.html | 0001477932-26-002252 |
| Document: 0001477932-26-002252-index.html | 0001477932-26-002252 |
| Document: 0001477932-26-002252.txt | 0001477932-26-002252 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | NT 10-K | $0.0300 | awaiting T+20 | — | $0.0459 (−53.00%) |
Apr 15, 2026 27w ago | 10-Q/A | $0.2100 $0.0850 | ▼ −59.52% | ▼ −65.57% | $0.0459 (−78.14%) |
Apr 15, 2026 27w ago | 10-Q/A | $0.2100 $0.0850 | ▼ −59.52% | ▼ −65.57% | $0.0459 (−78.14%) |
Apr 15, 2026 27w ago | 10-K/A | $0.2100 $0.0850 | ▼ −59.52% | ▼ −65.57% | $0.0459 (−78.14%) |
Apr 15, 2026 27w ago | 8-K | $0.2100 $0.0850 | ▼ −59.52% | ▼ −65.57% | $0.0459 (−78.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers